STAT News reports:
A large, Phase 3 study testing a Covid-19 vaccine being developed by AstraZeneca and the University of Oxford at dozens of sites across the U.S. has been put on hold due to a suspected serious adverse reaction in a participant in the United Kingdom.
A spokesperson for AstraZeneca, a frontrunner in the race for a Covid-19 vaccine, said in a statement that the company’s “standard review process triggered a pause to vaccination to allow review of safety data.”
It was not immediately clear who placed the hold on the trial, though it is possible it was placed voluntarily by AstraZeneca and not ordered by any regulatory agency.
Read the full article.
AstraZeneca pauses vaccine trial after suspected adverse event https://t.co/6hQ2Izl2wP
— Financial Times (@FinancialTimes) September 8, 2020
The #COVID19 vaccine Australia has invested in has been dealt a major setback after researchers uncovered a suspected serious adverse reaction in a trial participant #AstraZeneca #oxfordvaccine https://t.co/mhWpxKPrab
— The Courier-Mail (@couriermail) September 8, 2020
Through Operation Warp Speed, we're making unprecedented progress on a safe and effective vaccine. The @WhiteHouse Coronavirus Task Force met today to discuss vaccines in Phase 3 trials and plans for nationwide distribution.
— Mike Pence (@Mike_Pence) September 8, 2020
*PRESIDENT TRUMP CONSIDERS FAST-TRACKING UK'S ASTRAZENECA COVID-19 VACCINE BEFORE U.S. ELECTION – FT pic.twitter.com/W6esGDMBmC
— Investing.com (@Investingcom) August 23, 2020